Vitiligo is a chronic autoimmune disease characterized by loss of pigment of the skin,
affecting 0.5–2% of the population worldwide. It can have a significant impact on patients' …

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-
severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical …

Background Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds
to interleukin (IL)-13. Objectives To evaluate the efficacy and safety of lebrikizumab …

Abstract IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic
dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human …

Background Abrocitinib is a JAK‐1 selective inhibitor registered for the treatment of
moderate‐to‐severe atopic dermatitis (AD). Although efficacy and safety have been shown …

Atopic dermatitis (AD) in the elderly has recently emerged as a distinct subgroup of AD,
garnering widespread concern due to its increasing global incidence rate. Epidermal barrier …

Janus kinases (JAKs) are central components in cytokine signaling pathways. A number of
small molecule JAK inhibitors have been approved to treat a wide range of inflammatory and …

ABSTRACT Introduction Janus kinase inhibitors (JAKi) have dramatically improved the
treatment of various autoimmune and myeloproliferative disorders. Recently, concern has …

Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease. The Janus kinase
(JAK) has been identified as a target in AD, as it regulates specific inflammatory genes and …

JAK inhibitors target specific inflammatory cytokines involved in various inflammatory
diseases. Four molecules have been approved for dermatological use: upadacitinib …